Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102
Previously disclosed preclinical data supporting broad biodistribution across brain and spinal cord regions following lumbar intrathecal delivery of AAV9 gene therapy vectors in non-human primates
Symposium on Rett syndrome natural history data findings
DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company's analysis of the natural history study data at the 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, taking place in Boston from June 9-11, 2025. The three presentations will also be presented during a poster session on Monday, June 9, 2025, from 5:00-7:00 PM EST. Additional details on the meeting can be found at IRSF's website.
'We are excited to present data supporting our TSHA-102 clinical program and its potential to improve function or enable achievement of developmental milestones that would significantly improve quality of life. Importantly, these findings have increased our conviction in the differentiated potential of TSHA-102 to address the high unmet needs for patients and families suffering from this devastating disease,' said Sukumar Nagendran, M.D., President and Head of Research & Development at Taysha. 'We appreciate IRSF and their ongoing partnership, as well as the individuals with Rett syndrome, their caregivers and the clinicians who contributed to the important research that has increased our understanding of the disease progression and supported our alignment with the Food and Drug Administration (FDA) on a potential path to registration.'
2025 IRSF Rett Syndrome Scientific Meeting Oral Presentation Details
Title: REVEAL Adolescent/Adult and Pediatric Clinical Trial Update: Safety and Efficacy Data on TSHA-102 AAV9 Investigational Gene Therapy in Clinical Evaluation for Rett Syndrome Date/Time: Wednesday, June 11, 2025, 9:30 AM ESTSession: Industry UpdatesPresenters: Elsa Rossignol, M.D., FRCP, FAAP, Associate Professor in Neuroscience and Pediatrics at the Université de Montréal, Director of the Rett Multidisciplinary Clinic of the CHU Sainte-Justine and Principal Investigator of the REVEAL Adolescent/Adult and Pediatric trials
Title: Every Gain, Expanding Possibilities: Caregiver Insights on Meaningful Improvement in Rett Syndrome Gene Therapy (GT)Date/Time: Tuesday, June 10, 2025, 12:20 PM ESTSession: Biomarkers and Outcome MeasuresPresenters: Jenny Downs, MSc Ph.D., Program Head, Development and Disability at The Kids Research Institute Australia
Title: rAAV9 Vector Biodistribution in Brain and Spinal Cord via Lumbar Intrathecal Infusion in Nonnhuman Primates (NHP): Assessing the Administration Route Leveraged in TSHA-102 Rett Syndrome Clinical Trials Date/Time: Tuesday, June 10, 2025, 10:10 AM ESTSession: Model Systems Presenters: Fred Porter, Ph.D., Chief of Staff and Technical Operations Officer of Taysha
Taysha-Hosted Symposium: Gain and Regain of Developmental Milestones: How Natural History Insights are Redefining the Therapeutic Development for Rett SyndromeDate/Time: Tuesday, June 10, 2025, 7:30 AM ESTPresenter: Jeffrey Neul, M.D., Ph.D., Director, Vanderbilt Kennedy Center, Annette Schaffer Eskind Chair, Professor at the Vanderbilt University Medical Center, who served as Administrative Head of the Rett Syndrome Natural History Study
About TSHA-102TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.
About Rett SyndromeRett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.
About Taysha Gene TherapiesTaysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' 'plans,' and 'future' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, and our other product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials and making regulatory submissions, communications from the FDA on the regulatory pathway for TSHA-102, and the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (SEC) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2024, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.
Company Contact:Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc.hcollins@tayshagtx.com
Media Contact:Carolyn HawleyInizio EvokeCarolyn.hawley@inizioevoke.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
The Pink Salt Trick Recipe for Fast Weight Loss Trend in 2025: Why ProZenith Is the Science-Backed Alternative
Chicago, July 19, 2025 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. ProZenith is not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Individual results may vary. Always consult a healthcare provider before beginning any supplement or diet strategy. Click Here to Explore the Full ProZenith Formula TL;DR: A trending pink salt recipe is sweeping TikTok as a supposed shortcut for weight loss. But what's really behind this viral drink, and why are experts raising concerns? In this report, we break down the trend's rise, the controversy around AI-generated celebrity endorsements, and how the new supplement ProZenith aims to support hormonal metabolism in a safer, research-backed way. In This Release, You'll Discover: What the 'Pink Salt Trick' recipe really is — and how it became a top 2025 TikTok trend Why AI-generated celebrity videos are being used to fuel misinformation The health risks of using saltwater as a weight loss tool What medical professionals and dietitians are saying about the trend Why women over 30 are most vulnerable to wellness misinformation How ProZenith compares biologically to salt-based hacks What makes ProZenith a better option for long-term metabolic balance Click Here to Learn More About ProZenith What Is the Pink Salt Trick Recipe Everyone's Talking About? The pink salt trick refers to a homemade drink recipe that's gone viral on TikTok and YouTube. It's typically presented as a 'weight loss drink' or 'morning metabolism hack' involving: The Recipe: 1/2 teaspoon pink Himalayan or Hawaiian salt Juice from 1/2 lemon 8–12 oz of warm or room temperature water Optional: 1 tsp apple cider vinegar or a dash of cayenne pepper The promise? Drink it first thing in the morning to 'reset metabolism,' suppress appetite, detox the body, and kickstart fat loss — without caffeine or fasting. Videos promoting the recipe often use phrases like: 'My pants are literally falling off!' 'This is what celebrities are using now.' 'Better than Ozempic!' But the science behind these claims is flimsy at best. And in many cases, entirely fabricated. Despite anecdotal praise, there are no peer-reviewed studies supporting the metabolic effects of pink salt water. Experts say any perceived benefits are likely due to placebo or temporary hydration effects, not real fat loss. The Deepfake Endorsement Controversy: Why the Internet Believed Oprah Promoted the Pink Salt Trick While the drink itself has gone viral, much of the attention in 2025 stems from AI-generated videos of Oprah Winfrey praising the recipe. These videos are so realistic that thousands believed they were real endorsements. In reality, Oprah never promoted the pink salt trick — and she condemned such deepfake scams in a 2022 Instagram video, stating: 'It is a fraud. It is a fake. It's a lie. I have nothing to do with any weight loss gummies or pink salt drinks that claim I use them.' Despite this, new videos using AI facial mapping and voice-cloning tools continue to circulate. Social media platforms have struggled to moderate these videos in real time, which has only contributed to their virality. This issue was spotlighted in Yahoo's creator series — What's Up with the Oprah Pink Salt Trick Recipe for Weight Loss? and What's the Deal with the Miracle Pink Salt Trick for Weight Loss? — where journalist Cassandra Brooklyn described how the fake endorsements kept showing up in her feed even though she never searched for weight loss tips. These articles were later mentioned in a broader industry discussion, including coverage in a GlobeNewswire consumer briefing on ProZenith. Read: Pink Salt Recipe for Weight Loss Spotlighted in New Consumer Briefing on Metabolic Reset with ProZenith Why the Pink Salt Trick Doesn't Work — and Might Be Harmful According to Dr. Alison Childress, a registered dietitian at Texas Tech University: 'Too much sodium can lead to water retention… this could result in weight gain — not fat, but fluid — especially in those who are salt-sensitive.' While the drink may provide a fleeting sense of fullness, there's no thermogenic benefit, hormonal regulation, or appetite suppression involved. Moreover, repeated use of this drink without iodine-rich salt can increase the risk of iodine deficiency, particularly among women of reproductive age. Iodine plays a critical role in thyroid hormone production, and inadequate levels can lead to fatigue, cold sensitivity, dry skin, and weight gain — all symptoms ironically counterproductive to the goals of the pink salt drink. Why Women Over 30 Are Most Vulnerable to These Trends Many women over 30 experience hormonal changes that affect metabolism, energy, and cravings. As stress levels increase and sleep quality declines, quick-fix trends feel even more attractive. Wellness journalist Cassandra Brooklyn explains: 'The pink salt videos started showing up in my feed even though I never searched for them. It made me wonder how many other women were seeing them too — especially those actively looking for help.' Research published in the International Journal of Behavioral Medicine shows that women exposed to 'rapid weight loss' messaging experienced higher body dissatisfaction and stress eating patterns. Compounding the issue is the algorithmic nature of social media, which can push diet content to vulnerable audiences based on a few clicks or likes. For women experiencing hormonal shifts and psychological stress, these seemingly innocent videos can drive harmful behaviors. Why ProZenith Was Formulated for This Exact Challenge ProZenith is a non-stimulant supplement formulated to help women manage appetite, cravings, and metabolic sluggishness without trendy hacks or viral gimmicks. What's Inside: Magnesium + Calcium – Regulate cortisol and stabilize energy – Regulate cortisol and stabilize energy BHB (Beta-Hydroxybutyrate) – Mimics ketone states to curb cravings – Mimics ketone states to curb cravings Turmeric Extract (95% curcuminoids) – Supports inflammation reduction – Supports inflammation reduction BioPerine® – Enhances nutrient absorption and delivery Unlike the pink salt trick, ProZenith doesn't rely on a placebo effect. Its ingredients have been clinically reviewed to support appetite hormones like ghrelin, reduce emotional eating triggers, and help restore metabolic rhythm in women after 30. Each dose is designed for consistency — not intensity. There are no stimulants, no crashes, and no 'flush' reactions. Just gradual, supportive metabolic regulation backed by emerging science and nutritional precision. Explore the Full Ingredient Breakdown Read: ProZenith Ingredients Researched: The Science Behind the Popular Formula Final Thoughts: Why This Trend Matters More Than It Seems The pink salt trick may look harmless. But it reflects a deeper pattern: emotional marketing, AI misinformation, and health shortcuts with no science behind them. ProZenith doesn't promise overnight results. But it does offer a research-supported daily strategy for women who are tired of fads and ready for clarity. If you're navigating hormonal shifts, emotional cravings, or just want to feel steady again — don't fall for digital hype disguised as healing. Support your body with something that respects biology. Click Here to Learn How ProZenith Works About the Brand ProZenith is a non-stimulant nutritional supplement designed to support women navigating hormonal appetite shifts, stress cravings, and metabolism slowdown. With clinically supported ingredients and zero caffeine, ProZenith offers a daily ritual for consistent metabolic support — without buzzwords, gimmicks, or fake endorsements. Customer Support ProZenith – Anti-Craving Support Without Stimulants Email: [email protected] Order Help: Phone (US): 1-800-390-6035 Phone (INT): 1-208-345-4245 Disclaimer This article is for informational purposes only. ProZenith is not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Individual results may vary. Always consult a healthcare provider before beginning any supplement or diet strategy. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
9 hours ago
- Yahoo
FDA Announces Major Recall of Popular Deodorant
It's important to stay informed about recalls, because doing so truly impacts your life. Of course, the sooner you know about a recall, the better, because you can make sure to get rid of the suspecting item and keep everyone in your family safe. "Recalls are important because they protect the public from products that may cause injury, illness or even death," the Food and Drug Administration notes. Now, a large number of Power Stick deodorants manufactured by A.P. Deauville are being recalled for manufacturing defects, according to the Food and Drug Administration. The recall includes more than 67,000 cases of roll-on deodorants that were sold across the United Stated, according to a notice posted by the agency. The problem with the deodorants revolves around deviations with "current good manufacturing practices," a set of guidelines in the pharmaceutical manufacturing industry. The recalled deodorants include the Power Stick for her roll-on Antiperspirant Deodorant Powder Fresh, 1.8 oz/53 mL; the Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz/53 mL; and the Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz/ 53 mL. Find specific lot numbers on the FDA's website. A press release has not been issued for the recall as of yet. The status of the recall is ongoing. According to the FDA, "A recall is an action taken by a company to correct or remove from the market an FDA regulated product that violates U.S. laws and regulations." They add that "recalls may be initiated voluntarily by a company, or at the request of the FDA." More than 83,000 FDA regulated products were recalled between the years 2014 and 2024. The FDA adds that "most recalls involve removing violative FDA regulated products from the market, but there are instances where a violation can be corrected without removing the products from distribution."FDA Announces Major Recall of Popular Deodorant first appeared on Men's Journal on Jul 19, 2025 Solve the daily Crossword
Indianapolis Star
11 hours ago
- Indianapolis Star
Man dies after being sucked into MRI machine by his own metal necklace
A man who was violently sucked into an MRI machine by a metal chain around his neck has died, police in New York said. The man was wearing a large metallic chain around his neck, which caused him to be drawn into the machine, the Nassau County Police Department said in a news release. The incident took place at the Nassau Open MRI medical facility in the village of Westbury on the North Shore of Long Island. Police responded to the facility just after 4:30 p.m. on July 16. At the scene, witnesses told officers a 61-year-old man "entered an unauthorized M.R.I. room while the scan was in progress," police said. Multiple injuries in incident: Over 2 dozen people injured after vehicle crashes into crowd in Los Angeles He was transported to a local hospital where he was initially listed in critical condition. He died at the hospital on July 17 at 2:36 p.m., police said. Officials have not yet released the name of the man nor whether he was a visitor to the facility, a patient or if he worked there. Police did not elaborate on the type or extent of the man's injuries. According to police, the machine's magnetic field immediately attracted "a large metallic chain" the victim wore, which quickly pulled him into the machine and "resulted in a medical episode." The investigation into the incident is ongoing, police said. USA TODAY contacted Nassau Open MRI on July 18 but has not received a response. Magnetic resonance imaging, or MRI, is a non-invasive 3D imaging technology used to examine patients' organs, tissues and skeletal system for diagnostic purposes, according to the Mayo Clinic. Adverse events from MRI scans "are rare," according to the U.S. Food and Drug Administration (FDA), which regulates MRI equipment. Millions of MRI scans are performed across the nation every year, the FDA wrote on its website. The agency said it receives around 300 incident reports annually involving MRI scanners and coils from manufacturers, distributors, user facilities and patients. Most of the reports, according to the FDA, include burns, as well as injuries from "projectile events" (objects being drawn toward the MRI scanner). High-powered magnets in the machine quickly draw items, especially metal, into the machine's chamber. "The strong magnetic field can attract metallic objects, potentially causing them to become projectiles and injure patients," the FDA's website reads.
